Journal Article
. 2015 Mar;20(4).
doi: 10.1634/theoncologist.2014-0198.

In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?

Xavier Pivot 1 Laura Mansi 2 Loic Chaigneau 2 Philippe Montcuquet 2 Antoine Thiery-Vuillemin 2 Fernando Bazan 2 Erion Dobi 2 Jean L Sautiere 2 Frederic Rigenbach 2 Marie P Algros 2 Steve Butler 2 Farid Jamshidian 2 Phillip Febbo 2 Christer Svedman 2 Sophie Paget-Bailly 2 Franck Bonnetain 2 Christian Villanueva 2 
Affiliations
  • PMID: 25795632
  •     22 References
  •     3 citations

Abstract

Background: The Oncotype DX recurrence score (RS) assay has been validated for prediction of 10-year risk of distant recurrence and likelihood of benefit from chemotherapy in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer. Patients with high RS tumors have substantial benefit, and patients with low RS tumors have minimal if any benefit from chemotherapy. Tumor size is used as a key parameter when selecting patients for neoadjuvant chemotherapy. The aim of this study was to assess the distribution of RS in patients selected for neoadjuvant chemotherapy primarily according to tumor size.

Patients And Methods: Patients with ER-positive and HER2-negative tumors that were node-negative or had no more than 1 positive node from three trials were included in this study. Oncotype DX was performed at Genomic Health, Inc., blinded to the clinical data. Descriptive statistics were calculated for distribution of RS for all cases.

Results: Of 277 patients, 96 met eligibility criteria, and 81 had sufficient material for analysis. Median tumor size was 40 mm (interquartile range [IQR], 30-50 mm). Grade I, II, and III were observed in 13, 49, and 17 cases, respectively. There was a wide distribution of RS with a median of 21.4 (IQR, 16.05-26.75). In total, 23 (28.3%) had high, 28 (34.6%) intermediate, and 30 (37%) low RS results.

Conclusion: The RS may provide relevant information for neoadjuvant treatment decisions in select patients both in clinical practice and in studies. Inclusion of low RS disease patients in neoadjuvant trials will likely only dilute the ability to look at treatment effects.

Keywords: Breast cancer; Neoadjuvant chemotherapy; Oncotype DX; Recurrence score.

Feasibility of using tissue microarray cores of paraffin-embedded breast cancer tissue for measurement of gene expression: a proof-of-concept study.
Suzanne Drury, Janine Salter, +2 authors, Mitch Dowsett.
J Clin Pathol, 2010 May 26; 63(6). PMID: 20498025
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B Fisher, A Brown, +11 authors, N V Dimitrov.
J Clin Oncol, 1997 Jul 01; 15(7). PMID: 9215816
Highly Cited.
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Frederick L Baehner, Ninah Achacoso, +5 authors, Laurel A Habel.
J Clin Oncol, 2010 Aug 11; 28(28). PMID: 20697093
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis.
J Natl Cancer Inst, 2005 Feb 03; 97(3). PMID: 15687361
Highly Cited.
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Luca Gianni, Milvia Zambetti, +14 authors, Steven Shak.
J Clin Oncol, 2005 Sep 08; 23(29). PMID: 16145055
Highly Cited.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
Manfred Kaufmann, Gabriel N Hortobagyi, +17 authors, Gunter von Minckwitz.
J Clin Oncol, 2006 Apr 20; 24(12). PMID: 16622270
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Henri Roché, Pierre Fumoleau, +17 authors, Bernard Asselain.
J Clin Oncol, 2006 Nov 23; 24(36). PMID: 17116941
Highly Cited.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
M Kaufmann, G von Minckwitz, +16 authors, S Loibl.
Ann Oncol, 2007 Nov 14; 18(12). PMID: 17998286
Review.
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Paul Ellis, Peter Barrett-Lee, +22 authors, TACT Trialists.
Lancet, 2009 May 19; 373(9676). PMID: 19447249    Free PMC article.
Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.
A Thiery-Vuillemin, A Llombart-Cussac, +7 authors, X Pivot.
Breast, 2010 Aug 10; 20(1). PMID: 20692157
Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.
Veronique Lorgis, Marie Paule Algros, +10 authors, Xavier Pivot.
Breast, 2011 Feb 04; 20(3). PMID: 21288720
Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients.
Xiangnan Kong, Meena S Moran, +2 authors, Qifeng Yang.
Eur J Cancer, 2011 Jul 09; 47(14). PMID: 21737257
Review.
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Edith A Perez, Amylou C Dueck, +9 authors, Beiyun Chen.
J Natl Cancer Inst, 2011 Dec 06; 104(2). PMID: 22138096    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, +14 authors, Sibylle Loibl.
J Clin Oncol, 2012 Apr 18; 30(15). PMID: 22508812
Highly Cited.
Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy.
N Chaumard, S Limat, +7 authors, X Pivot.
Breast, 2011 Nov 30; 21(4). PMID: 22123411
Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
Christos Markopoulos.
Expert Rev Anticancer Ther, 2013 Feb 15; 13(2). PMID: 23406559
Review.
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.
Gary H Lyman, Sarah Temin, +12 authors, American Society of Clinical Oncology Clinical Practice.
J Clin Oncol, 2014 Mar 26; 32(13). PMID: 24663048
Highly Cited.
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.
G von Minckwitz, J-U Blohmer, +10 authors, German Breast Group.
Ann Oncol, 2004 Dec 16; 16(1). PMID: 15598939
The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.
Atilla Soran, Kaori Tane, Efe Sezgin, Rohit Bhargava.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285033    Free PMC article.
Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test.
Debbie M Jakubowski, Helen Bailey, +7 authors, Frederick L Baehner.
J Surg Oncol, 2020 Jun 05;. PMID: 32497318    Free PMC article.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Hiroji Iwata, Norikazu Masuda, +19 authors, Yasuo Ohashi.
Breast Cancer Res Treat, 2018 Sep 23; 173(1). PMID: 30242578    Free PMC article.